Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.42 |
| ▸ | TUBB | P07437 | 1/20 | 0.42 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.42 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.42 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.42 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.42 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.42 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.42 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL323109 | 0.89 | DYRK1A (0.49) | DYRK1ACLK4KDM4EGAACYP3A4 | |
| SCHEMBL18239968 | 0.85 | MAPT (0.43) | RXRARXRBKDM4EGAAMAPT | |
| SCHEMBL6382918 | 0.83 | CYP11B1 (0.44) | KDM4EGAAMAPTTDP1PDGFRB | |
| SCHEMBL8527534 | 0.83 | NQO1 (0.45) | KDM4EGAAMAPTTDP1TUBB4A | |
| SCHEMBL6194180 | 0.83 | TTK (0.43) | RXRARXRBKDM4EGAAMAPT | |
| SCHEMBL3197832 | 0.82 | KDM4E (0.43) | RXRARXRBKDM4EGAAMAPT | |
| SCHEMBL6963144 | 0.80 | MAPT (0.47) | RXRARXRBKDM4EGAAMAPT | |
| SCHEMBL8780023 | 0.80 | NFE2L2 (0.45) | DYRK1ACLK4GAACYP3A4NOTUM | |
| SCHEMBL8384916 | 0.79 | RXRA (0.44) | DYRK1ACLK4RXRARXRBMAPT | |
| SCHEMBL15067112 | 0.79 | NQO1 (0.48) | KDM4EMAPTTDP1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234041-A1 | Substituted 1-benzazepines and derivatives thereof | BIOPORT R&D, INC. | 2005-10-20 | — | — | US | disclosed |
| EP-1392317-A4 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | ANTEXPHARMA INC (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-1229913-A4 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | ANTEXPHARMA INC (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1392317-A2 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | Antexpharma, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-6514965-B1 | For treating bacterial infections | ANTEX PHARMA INC. | 2003-02-04 | — | — | US | disclosed |
| WO-2002100327-A2 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | ANTEXPHARMA, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-1229913-A1 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | Antexpharma, Inc. (US) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001035964-A1 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | ANTEXPHARMA, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234041-A1 | Substituted 1-benzazepines and derivatives thereof | BAK1, BAD, BAX | DYRK1A 3543/4885CLK4 2885/4885RXRA 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.